Although prostate-specific antigen (PSA) is a routine marker used for diagnosis and prognosis of PCa, its sensitivity is compromised by false-positive results, which might lead to overtreatment of indolent disease [3] and mislead treatment decisions at relapse [4]. This evidence concerns the gene KLK3 and posterior cortical atrophy.